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Molecular characterization of Mycobacterium tuberculosis complex isolates (genotyping) can be used by
public health programs to more readily identify tuberculosis (TB) transmission. The Centers for Disease
Control and Prevention’s National Tuberculosis Genotyping Service has offeredM. tuberculosis genotyping
for every culture-conﬁrmed case in the United States since 2004. The TB Genotyping Information Man-
agement System (TB GIMS), launched in March 2010, is a secure online database containing genotype
results linked with case characteristics from the national TB registry for state and local TB programs to
access, manage and analyze these data. As of September 2011, TB GIMS contains genotype results for
89% of all culture-positive TB cases for 2010. Over 400 users can generate local and national reports
and maps using TB GIMS. Automated alerts on geospatially concentrated cases with matching genotypes
that may represent outbreaks are also generated by TB GIMS. TB genotyping results are available to
enhance national TB surveillance and apply genotyping results to conduct TB control activities in the
United States.
Published by Elsevier B.V.Open access under CC BY-NC-ND license. 1. Introduction
Tuberculosis (TB) incidence in the United States declined from
10.4 per 100,000 population at the peak of TB resurgence in 1992
to 3.8 per 100,000 population in 2009 (Centers for Disease Control
and Prevention, 2010). At the current rate of decline, the goal of
eliminating TB (i.e., <1 case per 1 million persons) will not be
attainable in the foreseeable future unless new and innovative
strategies are implemented (Hill et al., 2010; Stop TB USA, 2010).
One of the molecular characterization techniques for Mycobacte-
rium tuberculosis complex, TB genotyping, enhances public health
surveillance by ﬁnding missed opportunities to detect and inter-
rupt TB transmission (Asghar et al., 2009; Castro et al., 1992; Oelt-
mann et al., 2009; Perri et al., 2011; Pevzner et al., 2010). Other
public health applications of TB genotyping include investigation
of potentially false-positive TB-culture results (Burman and Re-
eves, 2000; Fitzpatrick et al., 2004); distinguishing new infections
from recurrent TB (van Rie et al., 1999); conﬁrming suspected,
and discovering unsuspected, epidemiologic links between pa-
tients whose isolates have matching genotypes (Barnes and Cave,
2003; Golub et al., 2001; Jasmer et al., 1999); conﬁrming or refut-
ing suspected TB outbreaks (Barnes and Cave, 2003; Golub et al.,, MS-E10, Atlanta, GA 30333,
C BY-NC-ND license. 2001; Pevzner et al., 2010); and monitoring TB program perfor-
mance (Geng et al., 2002; Moonan and Weis, 2008; Kong et al.,
2002).
Beginning in 1993, the Centers for Disease Control and Preven-
tion (CDC) funded regional genotyping laboratories to support TB
control programs to perform outbreak investigations and epidemi-
ologic studies in select regions of the country (Castro and Jaffe,
2002). In 1996, CDC initiated a National Tuberculosis Genotyping
and Surveillance Network, which was a 5-year sentinel surveil-
lance project where isolates from 10,883 patients were genotyped
(Cowan and Crawford, 2002). Results from this sentinel study dem-
onstrated the potential for future applications of genotyping as
part of both patient and population-based TB prevention and con-
trol activities in the United States (Centers for Disease Control and
Prevention, 2004). Experiences from these efforts provided scien-
tiﬁc foundation for initiating a national genotyping surveillance
system in 2004 (Centers for Disease Control and Prevention, 2004).
Surveillance is a core public health activity for the control and
elimination of TB (Castro, 2007). CDC, through the National Tuber-
culosis Surveillance System (NTSS), monitors annual epidemiologic
trends of TB cases in the United States (Centers for Disease Control
and Prevention, 2009). Although NTSS is regarded as comprehen-
sive, and is notable for routinely disseminating annual case-based
reports (Centers for Disease Control and Prevention, 2009), it has
not includedM. tuberculosis genotyping results for individual cases.
Developing a national system that combines both patient and
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demiology and transmission dynamics and may accelerate the
implementation of new strategies to detect and respond to trans-
mission events.
We describe the major components of an enhanced national TB
surveillance system that includes the already-established infra-
structure of the National TB Surveillance System (NTSS), the Na-
tional TB Genotyping Service (NTGS), and creation of a new data
management system: the Tuberculosis Genotyping Information
Management System (TB GIMS), which integrates TB patient sur-
veillance data and M. tuberculosis genotype information.2. National Tuberculosis Surveillance System
TB control programs in the United States are directly managed
by state or local health departments, but receive some funding
and personnel from CDC (Binkin, 1999). Even though TB control
programs seek funding from federal, state, local and private
sources to conduct TB control activities (Centers for Disease Con-
trol and Prevention, 1995), budgets and structure of TB programs
vary considerably between jurisdictions.
As one of the essential components of a National Tuberculosis
Control Program, state and local health departments began report-
ing aggregate TB case counts to CDC in 1953 (Centers for Disease
control and Prevention 1995, 2009). In 1979, national TB surveil-
lance expanded to case-based reporting of incident TB cases, estab-
lishing a national registry (NTSS) (Centers for Disease Control and
Prevention, 2009). In 1993, the NTSS transitioned to an electronic
reporting registry that collected data on sociodemographic, clinical
and risk factor variables for individual patients to better identify
and monitor populations at risk for TB disease (Centers for Disease
Control and Prevention, 2009).3. National Tuberculosis Genotyping Service
In 2004, CDC established the NTGS by funding two regional ref-
erence laboratories to genotype at least one M. tuberculosis isolate
from each culture-positive TB case in the United States. Through
NTGS, TB genotyping is available to all TB control programs at no
cost to patients, healthcare providers, or health departments
(Centers for Disease Control and Prevention, 2005). CDC pays for
the shipping of isolates from public health laboratories to NTGS
laboratories. NTGS participation is voluntary and the degree to
which genotype data are utilized is determined by individual TB
programs.
NTGS laboratories routinely use two genotyping methods on all
M. tuberculosis complex isolates: spacer oligonucleotide typing
(spoligotyping) and mycobacterial interspersed repetitive unit–
variable number tandem repeat typing (MIRU–VNTR) (Kamerbeek
et al., 1997; Cowan et al., 2005; Kirihara et al., 1985; Supply et al.,
2001; Savine et al., 2002). These methods require small amounts of
culture, yield digital results, and have a short turn-around time
(Kirihara et al., 1985; Supply et al., 2001). Crude cell lysates are
prepared from isolates cultured on Lowenstein-Jensen slants,
7H10/11 agar plates, or non-radiometric 7H9-based broths such
as BACTECMGIT 960 (Kirihara et al., 1985). Luminex based spoligo-
typing (CEQ8000 Genetic Analyses System, Beckman Coultier, Ful-
lerton, CA) and MIRU-VNTR typing are performed as previously
described elsewhere (Cowan et al., 2005; Savine et al., 2002).
In April 2009, MIRU-VNTR analysis was expanded from 12 loci
to 24 loci using multiplex ampliﬁcation of 24 loci and size determi-
nation on ABI3130XL (Applied Biosystems LT., Carlsbad, CA) (Oele-
mann et al., 2007). Semi-automated analysis of electronic data and
reporting of genotyping results are accomplished by using a com-
bination of spreadsheet macros, a relational database, and GeneMapper (Applied Biosystems LT. Carlsbad, CA). IS6110-restriction
fragment length polymorphisms (IS6110-RFLP) ﬁngerprinting
(Cave et al., 1991) and retrospective 24-locus MIRU-VNTR analysis
are available upon request to further differentiate genotype clus-
ters (Cowan, 2008). Sub-cultures of all isolates are prepared for
long-term storage at the genotyping laboratories, and DNA prepa-
rations and electronic data are transferred to CDC periodically.
In NTGS, a genotype is deﬁned as a discrete combination of spo-
ligotype and 12-locus MIRU-VNTR results. To facilitate communi-
cation of genotype data, a national naming convention,
‘‘PCRType,’’ was developed. PCRType is designated as ‘‘PCR’’ fol-
lowed by ﬁve digits, which are assigned sequentially to every
genotype identiﬁed in the United States. A genotype cluster is de-
ﬁned as two or more cases with matching PCRTypes (i.e., indistin-
guishable spoligotype and 12-locus MIRU-VNTR) in a jurisdiction.
4. Tuberculosis Genotyping Information Management System
TB GIMS is a secure Web-based system that supports ongoing
systematic data collection of isolates, integrates genotype results
with surveillance data on cases and automates timely dissemina-
tion of information. TB GIMS provides a platform for accomplishing
ﬁve key features and functions described below that augment the
national TB surveillance system.
4.1. User roles
TB GIMS has various user rol-es and access levels (Table 1). Ac-
cess to TB GIMS is limited to registered users. State TB GIMS
administrators, who are selected by state public health ofﬁcials,
approve user registration requests and assign TB GIMS user roles
according to the job responsibilities of the individual applicant
and needs of the jurisdiction. TB GIMS users have access to patient
and genotype data within their jurisdiction. Program and public
health laboratory super users have primary responsibility for data
management. Standard users have access to data but cannot sub-
mit or edit records. All TB GIMS users have access to reports and
maps according to their assigned jurisdictions.
4.2. Features and Functions
The main features and functions of TB GIMS are as follows:
4.2.1. Create, submit, track, and manage M. tuberculosis isolate data
Isolate records are created by laboratory super users, who use a
Web-based form to upload information for an individual isolate or
a batch of isolates. These isolate records are submitted by the pub-
lic health laboratories to an NTGS laboratory for genotyping. Each
isolate record has a unique system-generated identiﬁer, state lab-
oratory tracking number, specimen collection date, ship date, and
information about submitting laboratory. Laboratory super users
are responsible for submitting, tracking, and managing these data,
and subsequently shipping the isolates to the NTGS laboratories.
NTGS laboratory users get email notiﬁcations when isolates are
submitted by public health laboratory super users. When genotype
results are uploaded by the NTGS laboratories using the unique
system generated identiﬁer, email notiﬁcations prompt TB control
programs to review results for linking and data management. TB
GIMS provides tools to monitor pending genotype results, and
query and edit isolate records.
4.2.2. Link patient and isolate records
Overall data management and the linking of surveillance and
isolate records are coordinated between super users and CDC
(Fig. 1). TB GIMS offers tools to link NTGS isolate records and NTSS
Table 1
User roles and functions in Tuberculosis Genotyping Information Management System (TB GIMS).
User role User type Available functions Access level
Laboratory super
users
TB laboratorians at public health laboratories Create, edit, and submit isolate records to genotyping
laboratories
Line-listed isolate record by
jurisdiction*
Query, manage, and export isolate records
Analyze and visualize genotyping information at
aggregate level by using reports and maps
Aggregate reports by
jurisdiction*
Submit requests for additional testing: IS6110-RFLP or
24-locus MIRU-VNTR
TB program super
users (state and
local)
Genotype coordinators, TB program managers,
epidemiologists, surveillance coordinators, or
nurses
Edit, query, and export isolate records Line-listed isolate records by
jurisdiction*
Query, manage, and export patient records Line-listed patient records by
jurisdiction*
Link isolate records to surveillance records to create
complete patient records
Analyze and visualize aggregate data by using reports
and maps
Aggregate reports and maps
by jurisdiction*
Submit requests for additional testing: IS6110-RFLP or
24-locus MIRU-VNTR
Detect potential outbreaks
TB program standard
users (state and
local)
TB program managers, epidemiologists, nurses, or
contact investigators
Query and export isolate records Line-listed isolate records by
jurisdiction*
Query and export patient records Line-listed patient records by
jurisdiction*
Analyze and visualize aggregate data by using reports
and maps
Aggregate reports and maps
by jurisdiction*
CDC users National laboratory super user
National program super and standard users
(epidemiologists, medical ofﬁcers, or public health
advisors)
Manage and oversee laboratory- related activities and
data at the national level
Line-listed isolate records by
jurisdiction* and United
States
Manage, analyze, visualize, and apply genotyping
information to coordinate national genotyping
surveillance activities
Line-listed patient records by
jurisdiction* and United
States
Detect potential outbreaks Aggregate reports and maps
by jurisdiction and United
States
Genotyping
laboratory users
TB laboratorians at the two contract genotyping
laboratories
Manage, edit, and export genotype results for isolate
records
Line-listed isolate records
* Jurisdiction was deﬁned at registration. Example of some jurisdictions include city, county or state.
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unique patient identiﬁer (Centers for Disease Control and Preven-
tion, 2009). This patient record combines genotype results from
NTGS with sociodemographic, clinical, and epidemiologic variables
from NTSS. A one-to-one relationship between surveillance and iso-
late records is maintained in the patient database, maps and reports.
If only one isolate is submitted per patient, TB GIMS automatically
links the genotype result with the patient record. For surveillance re-
cords that are linked to isolates with multiple genotype results that
match, TB GIMS automatically selects the ﬁrst result available and
links it with the patient record. If the multiple isolates have discrep-
ant genotype results, they are either reconciled by the super user to
select a single genotype result for the patient record or unselected,1 This record should not be considered a patient medical record, as genotyping
results are not performed in a manner consistent with CLIA (Clinical Laboratory
Improvement Amendments) regulations. Therefore genotyping data should not be
used for patient treatment and clinical management (http://wwwn.cdc.gov/clia/pdf/
PHSA_353.pdf).hence excluded from reports and maps. All individual isolate results
are still available in the isolate database.4.2.3. Query isolate and patient databases
All users can query, view, sort, and export line-listed data on
individual isolates within their jurisdictions. All non-laboratory
users can perform the same functions with patient records within
their jurisdiction. Isolate-related queries can be reﬁned according
to dates of specimen collection and shipping, laboratory tracking
number, and genotype results. Queries on patient records can be
reﬁned based on geography, sociodemographics, risk factors and
genotype.4.2.4. Generate reports and maps
All users can generate reports and maps of patient records
aggregated by genotype within speciﬁed jurisdictions. A patient
record is required for inclusion in these genotype cluster-level re-
ports and maps, which provide summaries of temporal, geo-
graphic, sociodemographic, clinical and risk characteristics of
Fig. 1. Data ﬂow and coordination of activities using Tuberculosis Genotyping Information Management System (TB GIMS).
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ﬁned date ranges based on user-selected date types (e.g., treatment
start date or report date) and geography (state or county). Users
can view data on patients from outside their assigned jurisdiction
aggregated at the state level in a national distribution report and
national map. The reports are produced in portable document for-
mat (PDF), so that they can be saved or printed. Based on the
assumption that geographically concentrated genotype clusters
are more likely to represent recent transmission, an ‘‘alert level’’
reﬂecting the degree of geospatial concentration of county-level
genotype clusters relative to the rest of the country can be gener-
ated by users through TB GIMS. Geospatial concentration scores
are calculated based on the number of cases in a genotype cluster
in a county as compared to the rest of the country for a retrospec-
tive 3-year period from the date of report generation. Alert levels
are based on geospatial concentration scores of log likelihood ratio
(LLR) values (Kulldorf, 1997), which are categorized as high, med-
ium and none based on pre-deﬁned cut-points. The higher the alert
level, the greater the likelihood of geographic clustering, sugges-
tive of recent transmission (Oren et al., 2010). Alert levels are avail-
able in selected TB GIMS reports. TB GIMS users are notiﬁed if a
cluster with two or more cases met the criteria for an alert level.
The following reports and maps are available in TB GIMS.
4.2.4.1. Surveillance Summary Report. Displays aggregate cross-tab-
ulations of case counts and percentages of selected socio-demo-
graphic, clinical, and risk characteristics comparing jurisdictional
data with data from the rest of the state or the country (Appendix
A).
4.2.4.2. Epidemic curve. Generates a histogram of case counts
aggregated by user selected period (month, quarter, or year) for
the user speciﬁed genotype (Appendix B).
4.2.4.3. County list of genotypes. Generates a list of county-level
genotype clusters in the user selected geographic area. Users can
sort clusters by ascending or descending number of cases, geno-types, or alert levels. The default sort order is descending alert lev-
els for prioritization of clusters from high geospatial concentration
to lower concentration (Appendix C).4.2.4.4. National distribution report. Tabulates the total number and
proportion of cases of a speciﬁed genotype in each state where it
has been identiﬁed (Appendix D).4.2.4.5. National, state and county maps. Choropleth maps illustrate
case counts for the user speciﬁed genotypes at the national, state,
and county level. Within their assigned state or county, users can
hover over individual counties and zip codes to view a list of aggre-
gate case counts and unique patient identiﬁers for that area. Geo-
spatial alert levels are also available in state and county level maps.
(Appendix E).4.2.5. Facilitate communication using TB GIMS directory
All users have access to contact information (email address and
phone number) for other users.4.3. Data security
In compliance with federal standards for patient conﬁdentiality,
no personally identiﬁable information (e.g., name, date of birth, or
address) is entered in TB GIMS (National Institute of Standards and
Technology 2010). Because TB GIMS is located on a federal govern-
ment computer server and contains information exchanged be-
tween CDC and external public health partners, such as state and
local health departments, CDC is responsible for maintaining
appropriate credentialing according to federal law (E-Government
Act, FISMA, 2002). Data use and sharing agreements were ap-
proved by an ofﬁcial in each state before surveillance data were
loaded into TB GIMS. Data integrity is maintained by limiting edit-
ing functions to a select group of super users in each jurisdiction
(Table 1). Further, surveillance records from NTSS cannot be edited
using TB GIMS.
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TB GIMS was developed over a four-year period using federal
funds through a contract mechanism and direct full-time employee
(FTE) support. Approximately 21,000 person-hourswere used to de-
sign, build, and pilot test TB GIMS. In the ﬁrst year after release, an
additional 8400 person-hours were spent on operational support,
maintenance, and technical enhancements. A TB GIMS Advisory
group comprising of two federal, eight state, and two local TB pro-
grampartners provided input into the general structure and speciﬁc
functions of TB GIMS through monthly conference calls. Genotype
coordinators or epidemiologists (mostly TB GIMS super users)
provide routine input through monthly conference calls that con-
tinue to date. All previous NTGS results and corresponding patient
surveillance records were loaded into TB GIMS before release.
Monthly training webinars during March–June 2010 oriented
users to TB GIMS. Self-study manuals, interactive training videos,
an online glossary, help desk support, and a data dictionary are
available to all users. As of September 2011, TB GIMS had more
than 500 registered users, over 400 active users and contained
71,078 isolate records and 58,769 linked case records (83%). User
groups meet monthly via teleconference to discuss data manage-
ment issues and provide feedback for continued enhancements.
5. National tuberculosis genotyping surveillance coverage
Several steps are essential for TB control programs to ensure
that all culture-positive TB cases are included in national TB geno-
typing surveillance. These include submission of isolates for geno-
typing, subsequent linking of genotyping results with TB case
surveillance records and transmission of surveillance records to
CDC. National TB genotyping surveillance coverage is deﬁned as
the proportion of reported culture-positive TB cases with a geno-
type result. National genotyping surveillance coverage increased
from 51% in 2004 to 89% in 2010 (Fig. 2). Fifteen states had geno-
typing coverage <50% in 2004 compared to only two states in 2009
(data not shown). In 2004, four states had 100% coverage; this in-
creased to 12 states in 2010. TB programs can monitor their na-Fig. 2. National tuberculosis genotyping sutional TB genotyping surveillance coverage through the National
Tuberculosis Indicator Project (NTIP) (http://www.cdc.gov/tb/pub-
lications/factsheets/statistics/NTIP.htm).
TB GIMS had a meaningful impact on national TB genotyping
surveillance coverage. For example, in 2008, prior to TB GIMS
implementation, 66% (6662 of 10,030) of culture-conﬁrmed TB
cases had linked genotype results. After TB GIMS implementation,
users were able to update the database and link previously re-
ported cases and isolates within the system. When coverage was
re-calculated for the same year, 80% (8063 of 10,030) of culture-
conﬁrmed TB cases had linked genotype results. This was a 14% in-
crease in coverage for 2008. TB GIMS’ user-friendly tools for linking
isolate and surveillance records led to improved data management
and increased coverage.
Additionally, with the launch of TB GIMS, at least one jurisdic-
tion identiﬁed culture-conﬁrmed cases that were not reported to
NTSS but had genotyped isolates. Follow-up on these isolates led
to improved reporting of TB cases to NTSS (T. Goins, personal com-
munication, May 25, 2011).
6. Challenges, limitations and opportunities
Establishing a national TB genotyping surveillance system re-
quires ongoing, systematic collection, analysis, interpretation,
and dissemination of both genotype and TB patient-level informa-
tion. Traditional TB surveillance is dependent on case deﬁnitions
limited to person, place and time. Variables that characterize M.
tuberculosis complex expand TB surveillance from a case-based ap-
proach, to a more comprehensive host-agent approach. TB GIMS
offers the ability to integrate a host-agent perspective into routine
TB surveillance activities in the United States.
6.1. Molecular epidemiology methods
Although spoligotyping and 12-locus MIRU-VNTR, the primary
genotyping methods used by NTGS, have good discriminatory
power, these methodsmay not provide sufﬁcient resolution for clo-
sely related genotype (Sandegren et al., 2011). The expanded panelrveillance, United States, 2004–2010.
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the deﬁnition of a ‘‘genotype’’ to includematching on all 24 loci. Pre-
liminary data suggest that using 24-locus MIRU-VNTR to deﬁne a
genotype may divide some large genotype clusters into smaller
and potentially more meaningful groups, increasing the speciﬁcity
of genotype cluster deﬁnitions (Cowan L, 2008).
6.2. Data management
Data management was a critical gap in U.S. TB genotyping sur-
veillance before implementation of TB GIMS. Findings from a 2004
survey conducted by National Tuberculosis Controller’s Association
revealed that even though 46 TB control programs out of 52 who
responded to this survey (88%) were sending isolates for genotyp-
ing, only 12 programs (23%) routinely linked genotyping results
with surveillance records using Microsoft Excel or Access dat-
abases (Moonan et al., 2006). TB GIMS responded to this need by
providing a standardized data management system to access, man-
age, and review TB genotyping data more efﬁciently and link those
data to surveillance data more efﬁciently.
6.3. Analytic and visualization tools
Analytic and visualization tools have provided an improved
platform to facilitate analyses and utilization of TB case- and clus-
ter-level information for TB control activities. Individual queries
and aggregated data reports are designed to help TB control pro-
grams conﬁrm or refute suspected chains of TB transmission and
enhance contact investigation efforts, an essential component of
the United States TB elimination strategy (Stop TB USA, 2010).
The tools and functions in TB GIMS can be used to compare and
monitor emerging or growing genotype clusters in space and time,
within and between jurisdictions, and to detect epidemiologic
shifts. These data may prove useful for identifying outbreaks soon-
er and for tailoring an appropriate public health response. National
maps and distribution reports may provide insight into the preva-
lence and geographic distribution of speciﬁc genotypes ofM. tuber-
culosis. The TB GIMS directory supports increased coordination on
genotype cluster investigations involving multiple jurisdictions.
6.4. National genotyping surveillance coverage
To accurately interpret genotyping data and identify recent TB
transmission, high national TB genotyping surveillance coverage is
essential. Despite substantial improvements in national coverage
since 2004, limited resources have led some jurisdictions to submit
isolates selectively. Selective genotyping (i.e., submitting isolates
according to select criteria) can be useful for some applications
(e.g., investigating false-positive cultures and conﬁrming known epi-
demiologic links); however, it does not support other applications,
such as identifying unknown epidemiologic links and detecting
outbreaks. Unfortunately, the drawbacks of selective genotyping
can extend beyond jurisdictional borders by inﬂuencing outbreak
detection algorithms, which are based on identifying aberrations in
the geospatial distribution of patients with matching genotypes.
6.5. Using TB genotyping and TB GIMS in TB control activities
Although genotyping data are widely available to TB programs,
understanding and applying this information are critical to ensure
that they are used in routine TB control activities. From a survey of
119 TB GIMS users six months after launch of TB GIMS, ‘‘conﬁrming
or refuting epidemiologic links’’ was reported as the most common
application of genotyping by 66% of TB GIMS users. Forty-ﬁve per-
cent of TB GIMS users reported using genotyping to detect out-
breaks (Baker et al., 2011). Future evaluations of TB GIMS willexamine the overall utility of the system for routine applications
of genotyping and examine the speciﬁcity and sensitivity of TB
GIMS alerts for detecting outbreaks.
Another important attribute of an effective surveillance system is
timeliness (Teutsch SM, 2000). Eighty-ﬁve percent of the userswere
satisﬁed with the system as a whole but only 20% of the users were
satisﬁed with its timeliness (Baker et al., 2011). There are multiple
factors that inﬂuence the timeliness of genotyping data.M. tubercu-
losis is a slowgrowing organism, so obtaining a culturemay take 2 to
8 weeks. Additionally, many jurisdictions submit isolates to the
NTGS laboratories in batches and the timing of submissions depends
on the TB incidence and laboratory capacity in each jurisdiction. To
partially overcome this challenge andminimize the ﬁnancial impact
of genotyping on public health laboratories, CDC pays for shipping
isolates from public health laboratories to NTGS laboratories. A sys-
tem analysis revealed that isolates submitted for genotyping during
May 2010–July 2010 showed a median time from specimen collec-
tion to creation of a complete patient record in TB GIMS of 142 days
(Range: 31–359 days) (Baker et al., 2011).Moreover, the survey sug-
gested that results availablewithin 2 months of specimen collection
would be acceptable for application of genotyping results into rou-
tine TB control activities (Baker et al., 2011). However, the time for
culture growth, batching and cost of shipping isolates are not the
only limitations. Creating a complete patient record in TB GIMS
requires proactive datamanagement and coordination among labo-
ratory, program and surveillance personnel. Delays in datamanage-
mentmay occurwhen transferring surveillance variables from local
paper and electronic logs to state surveillance systems, or when
assigning, verifying, and transmitting surveillance records from
local to state systems to NTSS.
Survey ﬁndings also suggest that for real-time application of
genotyping, complete patient records should be available within
4 months of specimen collection, while the patient is early in treat-
ment and most likely within the public health system. These ﬁnd-
ings and additional evaluation studies will inform development of
standards for timeliness and capacity building that will enhance
usefulness and improve attributes of TB GIMS. Now that we have
an established system, future studies will need to examine the im-
pact and utility of the system and TB genotyping in general on
improving TB control activities. In particular, systematic cost-effec-
tiveness analyses are needed to quantify the programmatic impact
of TB GIMS as well as resources needed to maintain and success-
fully use the system.7. Conclusion
TB GIMS represents the successful merger of three scientiﬁc
ﬁelds: surveillance, bacterial genetics, and informatics. This inte-
gration creates a unique opportunity to expand case-based public
health surveillance to a host-agent surveillance system that is ro-
bust and useful with a potential to be an early TB outbreak detec-
tion system. Technological advances in laboratory science, evolving
TB epidemiology, and ongoing changes to the structure of public
health programs require that the design and functions of this na-
tional genotype surveillance system remain responsive to the
changing needs of TB control in the future. Continued enhance-
ments to TB genotyping with new and innovative tools such as
molecular detection of drug resistance and whole genome
sequencing (Schurch et al., 2010) may be integrated in TB GIMS
to create more comprehensive molecular characterization and im-
proved tools for outbreak detection, alerting, and response.
This surveillance information also has the potential to inform
program evaluation and policy development by supporting evi-
dence-based decision making and inﬂuencing practices focused
on the elimination of TB in the United States.
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